Evaluation of new gastro-intestinal prokinetic (ENGIP-II) study.
Non-ulcer dyspepsia is a common clinical disorder characterised by reduced gastric motility. Safety concerns have restricted use of currently available prokinetic drugs. Itopride is a new safer prokinetic drug with dopamine D2 antagonism and acetylcholinesterase inhibitory actions. The ENGIP-II study was conducted to investigate the efficacy, and safety of itopride in patients of non-ulcer dyspepsia. There were significant reductions in upper abdominal pain, heartburn frequency, gastro-oesophageal regurgitation, nausea, bloating, early satiety after meals at day 3 only; whereas significant improvements were noted in belching, anorexia at day 6 and in vomiting at day 9. Thus, ENGIP-II study shows that itopride was well tolerated patients and appears to be the drug of choice in patients with non-ulcer dyspepsia.
Walwaikar
Pradeep P
PP
JB Chemicals & Pharmaceuticals Limited, Mumbai 400030.
Kulkarni
Sujay S
SS
Bargaje
Rahul S
RS
D000110:Acetylcholinesterase / Q000187:drug effects; D000328:Adult; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use*; D001593:Benzyl Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D065127:Dopamine D2 Receptor Antagonists; D004415:Dyspepsia / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012449:Safety; D016896:Treatment Outcome
D001549:Benzamides; D001593:Benzyl Compounds; D065127:Dopamine D2 Receptor Antagonists; C102254:itopride; D000110:Acetylcholinesterase